These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25388285)

  • 61. Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination.
    Ochyl LJ; Moon JJ
    J Vis Exp; 2015 Apr; (98):e52771. PubMed ID: 25992469
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hesperetin as an adjuvant augments protective anti-tumour immunity responses in B16F10 melanoma by stimulating cytotoxic CD8
    Jiang S; Wang S; Zhang L; Tian L; Li L; Liu Z; Dong Q; Lv X; Mu H; Zhang Q; Wang B
    Scand J Immunol; 2020 Apr; 91(4):e12867. PubMed ID: 31975405
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Using magnetic resonance imaging to evaluate dendritic cell-based vaccination.
    Ferguson PM; Slocombe A; Tilley RD; Hermans IF
    PLoS One; 2013; 8(5):e65318. PubMed ID: 23734246
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
    Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
    Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory.
    Leleux JA; Albershardt TC; Reeves R; James R; Krull J; Parsons AJ; Ter Meulen J; Berglund P
    PLoS One; 2021; 16(12):e0259301. PubMed ID: 34855754
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
    Khalil DN; Suek N; Campesato LF; Budhu S; Redmond D; Samstein RM; Krishna C; Panageas KS; Capanu M; Houghton S; Hirschhorn D; Zappasodi R; Giese R; Gasmi B; Schneider M; Gupta A; Harding JJ; Moral JA; Balachandran VP; Wolchok JD; Merghoub T
    J Clin Invest; 2019 Jul; 129(8):3435-3447. PubMed ID: 31329159
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.
    Matzner P; Sorski L; Shaashua L; Elbaz E; Lavon H; Melamed R; Rosenne E; Gotlieb N; Benbenishty A; Reed SG; Ben-Eliyahu S
    Int J Cancer; 2016 Apr; 138(7):1754-64. PubMed ID: 26453448
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination.
    Zhu D; Hu C; Fan F; Qin Y; Huang C; Zhang Z; Lu L; Wang H; Sun H; Leng X; Wang C; Kong D; Zhang L
    Biomaterials; 2019 Jun; 206():25-40. PubMed ID: 30925286
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro evaluation of TLR4 agonist activity: formulation effects.
    Misquith A; Fung HW; Dowling QM; Guderian JA; Vedvick TS; Fox CB
    Colloids Surf B Biointerfaces; 2014 Jan; 113():312-9. PubMed ID: 24121074
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Soluble antigen traffics rapidly and selectively from the corneal surface to the eye draining lymph node and activates T cells when codelivered with CpG oligonucleotides.
    Dang Z; Kuffová L; Liu L; Forrester JV
    J Leukoc Biol; 2014 Mar; 95(3):431-40. PubMed ID: 24295832
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI.
    Brewer KD; Lake K; Pelot N; Stanford MM; DeBay DR; Penwell A; Weir GM; Karkada M; Mansour M; Bowen CV
    Vaccine; 2014 Dec; 32(51):6956-6962. PubMed ID: 25444822
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination.
    Najibi AJ; Lane RS; Sobral MC; Bovone G; Kang S; Freedman BR; Gutierrez Estupinan J; Elosegui-Artola A; Tringides CM; Dellacherie MO; Williams K; Ijaz H; Müller S; Turley SJ; Mooney DJ
    Nat Biomed Eng; 2024 Oct; 8(10):1226-1242. PubMed ID: 38710838
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Altering Antigen Charge to Control Self-Assembly and Processing of Immune Signals During Cancer Vaccination.
    Tsai SJ; Amerman A; Jewell CM
    Front Immunol; 2020; 11():613830. PubMed ID: 33488621
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy.
    Tian R; Ke C; Rao L; Lau J; Chen X
    Adv Drug Deliv Rev; 2020; 161-162():145-160. PubMed ID: 32827558
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of Toll-like receptor 4 polymorphisms in vaccine immune response.
    Pellegrino P; Falvella FS; Cheli S; Perrotta C; Clementi E; Radice S
    Pharmacogenomics J; 2016 Feb; 16(1):96-101. PubMed ID: 25823688
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Shortwave-infrared-light-emitting probes for the in vivo tracking of cancer vaccines and the elicited immune responses.
    Ren F; Wang F; Baghdasaryan A; Li Y; Liu H; Hsu R; Wang C; Li J; Zhong Y; Salazar F; Xu C; Jiang Y; Ma Z; Zhu G; Zhao X; Wong KK; Willis R; Christopher Garcia K; Wu A; Mellins E; Dai H
    Nat Biomed Eng; 2024 Jun; 8(6):726-739. PubMed ID: 37620621
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery.
    An M; Li M; Xi J; Liu H
    ACS Appl Mater Interfaces; 2017 Jul; 9(28):23466-23475. PubMed ID: 28640587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, Synthesis, and Bioactivity Evaluation of a TF-Based Cancer Vaccine Candidate Using Lipid A Mimetics As a Built-In Adjuvant.
    Gao L; Li G; Qiu C; Ye Y; Li X; Liao P; Ming W; Liu Z; Luo X; Liao G
    J Med Chem; 2024 Jun; 67(12):9976-9990. PubMed ID: 38886162
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lymph node targeting strategies to improve vaccination efficacy.
    Jiang H; Wang Q; Sun X
    J Control Release; 2017 Dec; 267():47-56. PubMed ID: 28818619
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases.
    Gu Y; Yang J; He C; Zhao T; Lu R; Liu J; Mo X; Wen F; Shi H
    Signal Transduct Target Ther; 2023 Jul; 8(1):273. PubMed ID: 37455272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.